普拉克索联合多巴丝肼治疗帕金森病患者的效果

Effects of Pramipexole combined with Doxycycline in treatment of patients with Parkinson’s disease

目的:观察普拉克索联合多巴丝肼治疗帕金森病患者的效果。方法:选取2021年3月至2023年3月该院收治的86例帕金森病患者进行前瞻性研究,按随机数字表法将其分为研究组和对照组各43例,对照组予以多巴丝肼治疗,研究组在对照组基础上联合普拉克索治疗,比较两组临床疗效,治疗前后Hoehn-Yahr分级、非运动症状控制[非运动症状评价量表(NMSS)]评分、血清miR-124和miR-137水平、认知功能[蒙特利尔认知量表(MOCA)]评分和生命质量[帕金森患者生活质量问卷(PDQ-39)]评分,以及不良反应发生率。结果:研究组治疗总有效率为95.35%(41/43),高于对照组的81.40%(35/43),差异有统计学意义(P<0.05);治疗后,研究组Hoehn-Yahr分级优于对照组,差异有统计学意义(P<0.05);研究组病情严重程度、发生频率等NMSS评分均低于对照组,差异有统计学意义(P<0.05);研究组血清miR-124水平高于对照组,血清miR-137水平低于对照组,差异均有统计学意义(P<0.05);研究组MOCA评分高于对照组,PDQ-39评分低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:普拉克索联合多巴丝肼治疗帕金森病患者可提高治疗总有效率、血清miR-124水平和MOCA评分,降低血清miR-137水平、NMSS评分和PDQ-39评分,改善Hoehn-Yahr分级,效果优于单纯多巴丝肼治疗。

Objective:To observe effects of Pramipexole combined with Doxycycline in treatment of patients with Parkinson’s disease.Methods:A prospective study was conducted on 86 patients with Parkinson’s disease admitted to the hospital from March 2021 to March 2023.According to the random number table method,they were divided into study group and control group,43 cases in each group.The control group was treated with Doxycycline,while the study group was treated with Pramipexole on the basis of that of the control group.The clinical efficacy,the Hoehn-Yahr staging,the non-motor symptom control[non-motor symptom scale(NMSS)]score,the serum miR-124 and miR-137 levels,the cognitive function[Montreal cognitive assessment(MOCA)]score,the quality of life[Parkinson’s quality of life questionnaire(PDQ-39)]score before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 95.35%(41/43),which was higher than 81.40%(35/43)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the Hoehn-Yahr staging in the study group was better than that in the control group,and the difference was statistically significant(P<0.05).The NMSS scores such as the severity and frequency of the disease in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The level of serum miR-124 in the study group was higher than that in the control group,the level of serum miR-137 was lower than that in the control group,and the differences were statistically significant(P<0.05).The MOCA score of the study group was higher than that of the control group,the PDQ-39 score was lower than that of the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Pramipexole combined with Doxycycline in the treatment of Parkinson’s disease can improve the total effective rate of treatment,the serum miR-124 levels and the MOCA scores,reduce the serum miR-137 levels,the NMSS scores and the PDQ-39 scores,and improve the Hoehn-Yahr staging.Moreover,it is superior to single Doxycycline treatment.